Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016:2016:8738959.
doi: 10.1155/2016/8738959. Epub 2016 Aug 8.

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

A Sánchez  1 , L R Brun  2 , H Salerni  3 , P R Costanzo  3 , D González  4 , A Bagur  4 , B Oliveri  5 , M B Zanchetta  6 , V Farías  6 , L Maffei  7 , V Premrou  7 , J L Mansur  8 , M S Larroudé  9 , M A Sarli  6 , P Rey  6 , M R Ulla  10 , M M Pavlove  11 , S Karlsbrum  11 , M L Brance  12
Affiliations

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

A Sánchez et al. J Osteoporos. 2016.

Abstract

The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BP-prior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMD and decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Change in BMD after 1 year of treatment with Dmab. ∗ indicates significant differences from basal (p < 0.0001).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Schurman L., Bagur A., Claus-Hermberg H., et al. Guidelines for the diagnosis, prevention and treatment of osteoporosis, 2012. Medicina (B Aires) 2013;73(1):55–74. - PubMed
    1. Cummings S. R., Martin J. S., McClung M. R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. The New England Journal of Medicine. 2009;361(8):756–765. doi: 10.1056/nejmoa0809493. - DOI - PubMed
    1. Dempster D. W., Lambing C. L., Kostenuik P. J., Grauer A. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clinical Therapeutics. 2012;34(3):521–536. doi: 10.1016/j.clinthera.2012.02.002. - DOI - PubMed
    1. Baron R., Ferrari S., Russell R. G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48(4):677–692. doi: 10.1016/j.bone.2010.11.020. - DOI - PubMed
    1. Papapoulos S., Chapurlat R., Libanati C., et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. Journal of Bone and Mineral Research. 2012;27(3):694–701. doi: 10.1002/jbmr.1479. - DOI - PMC - PubMed

LinkOut - more resources